Loading organizations...
Livzon Pharmaceutical Group develops, manufactures, and distributes a comprehensive range of pharmaceutical products. The company specializes in biopharmaceuticals, specialty drugs, and high-barrier complex preparations, including innovative diagnostic kits and therapeutic agents. Its portfolio addresses various medical conditions. Livzon employs a dual strategy, prioritizing novel drug development and advanced preparation technologies.
Founded in January 1985, Livzon Pharmaceutical Group has grown into a significant entity within the Chinese pharmaceutical landscape. Its establishment marked a commitment to advancing medical solutions. Over decades, the company continuously expanded its operational scope and research capabilities, driven by evolving healthcare needs.
Livzon's products serve healthcare providers and patients in need of specialized treatments, focusing on therapeutic areas like oncology and autoimmune diseases. The company is dedicated to human health, aiming to deliver leading, internationally competitive medicines. Livzon envisions becoming a world-class pharmaceutical enterprise, contributing to the national pharmaceutical industry through sustained innovation.
Key people at Livzon Pharmaceutical Group.
Livzon Pharmaceutical Group has 2 tracked investments across 2 companies. The latest tracked deal is $45.0M Series C in Atom Bioscience & Pharmaceutical in January 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 5, 2022 | Atom Bioscience & Pharmaceutical | $45.0M Series C | Yuhang Teng, Huang PU | Efung Capital, Hongshan Capital Group (Sequoia Capital China), Kaitai Capital, Unifortune Investment Holdings Group |
| Oct 2, 2019 | Elicio Therapeutics | $33.0M Series B | — | Efung Capital |
Key people at Livzon Pharmaceutical Group.
